Fengyun Hao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fengyun Hao has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Chong Sun
The Affiliated Hospital of Qingdao University
1 shared publication- Jiansheng Li
Department of Abdominal Ultrasound, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
1 shared publication Kejun Zhang
The Affiliated Hospital of Qingdao University
1 shared publication- Kejun Zhang
The Affiliated Hospital of Qingdao University
1 shared publication Liang Ning
The Affiliated Hospital of Qingdao University
1 shared publication- Qian An
Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia
1 shared publication
Latest Publications
- Open Access
- 4 May 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-12
Immune cell signatures and inflammatory mediators: unraveling their genetic impact on chronic kidney disease through Mendelian randomization
Prior research has established associations between immune cells, inflammatory proteins, and chronic kidney disease (CKD). Our Mendelian randomization study aims to elucidate the genetic causal relationships among these factors and CKD. We applied Mendelian randomization using genetic variants associated with CKD from a large genome-wide association study (GWAS) and inflammatory markers from a comprehensive GWAS summary. The causal links between exposures (immune cell subtypes and inflammatory proteins) and CKD were primarily analyzed using the inverse variance-weighted, supplemented by sensitivity analyses, including MR-Egger, weighted median, weighted mode, and MR-PRESSO. Our analysis identified both absolute and relative counts of CD28 + CD45RA + CD8 + T cell (OR = 1.01; 95% CI = 1.01–1.02; p < 0.001, FDR = 0.018) (OR = 1.01; 95% CI = 1.00–1.01; p < 0.001, FDR = 0.002), CD28 on CD39 + CD8 + T cell(OR = 0.97; 95% CI = 0.96–0.99; p < 0.001, FDR = 0.006), CD16 on CD14–CD16 + monocyte (OR = 1.02; 95% CI = 1.01–1.03; p < 0.001, FDR = 0.004) and cytokines, such as IL-17A(OR = 1.11, 95% CI = 1.06–1.16, p < 0.001, FDR = 0.001), and LIF-R(OR = 1.06, 95% CI = 1.02–1.10, p = 0.005, FDR = 0.043) that are genetically predisposed to influence the risk of CKD. Moreover, the study discovered that CKD itself may causatively lead to alterations in certain proteins, including CST5(OR = 1.16, 95% CI = 1.09–1.24, p < 0.001, FDR = 0.001). No evidence of reverse causality was found for any single biomarker and CKD. This comprehensive MR investigation supports a genetic causal nexus between certain immune cell subtypes, inflammatory proteins, and CKD. These findings enhance the understanding of CKD's immunological underpinnings and open avenues for targeted treatments.
- 4 May 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-12
Open AccessImmune cell signatures and inflammatory mediators: unraveling their genetic impact on chronic kidney disease through Mendelian randomization
Prior research has established associations between immune cells, inflammatory proteins, and chronic kidney disease (CKD). Our Mendelian randomization study aims to elucidate the genetic causal relationships among these factors and CKD. We applied Mendelian randomization using genetic variants associated with CKD from a large genome-wide association study (GWAS) and inflammatory markers from a comprehensive GWAS summary. The causal links between exposures (immune cell subtypes and inflammatory proteins) and CKD were primarily analyzed using the inverse variance-weighted, supplemented by sensitivity analyses, including MR-Egger, weighted median, weighted mode, and MR-PRESSO. Our analysis identified both absolute and relative counts of CD28 + CD45RA + CD8 + T cell (OR = 1.01; 95% CI = 1.01–1.02; p < 0.001, FDR = 0.018) (OR = 1.01; 95% CI = 1.00–1.01; p < 0.001, FDR = 0.002), CD28 on CD39 + CD8 + T cell(OR = 0.97; 95% CI = 0.96–0.99; p < 0.001, FDR = 0.006), CD16 on CD14–CD16 + monocyte (OR = 1.02; 95% CI = 1.01–1.03; p < 0.001, FDR = 0.004) and cytokines, such as IL-17A(OR = 1.11, 95% CI = 1.06–1.16, p < 0.001, FDR = 0.001), and LIF-R(OR = 1.06, 95% CI = 1.02–1.10, p = 0.005, FDR = 0.043) that are genetically predisposed to influence the risk of CKD. Moreover, the study discovered that CKD itself may causatively lead to alterations in certain proteins, including CST5(OR = 1.16, 95% CI = 1.09–1.24, p < 0.001, FDR = 0.001). No evidence of reverse causality was found for any single biomarker and CKD. This comprehensive MR investigation supports a genetic causal nexus between certain immune cell subtypes, inflammatory proteins, and CKD. These findings enhance the understanding of CKD's immunological underpinnings and open avenues for targeted treatments.
- Open Access
- 30 January 2024
- Published by Wiley
Targeting PEAK1 sensitizes anaplastic thyroid carcinoma 8505C cells to BRAFV600E inhibitor Vemurafenib in vitro
Vemurafenib, one of the selective BRAF inhibitor, is less effective in BRAF-mutant thyroid cancer, including anaplastic thyroid cancer (ATC), the mechanisms of which are still lacking. Pseudopodium-enriched atypical kinase 1 (PEAK1) has been demonstrated to be upregulated in human malignancies. Enhanced PEAK1 expression facilitates tumor cell survival and chemoresistance. Here we investigated the role and mechanisms of targeting PEAK1 in reversing vemurafenib resistance in ATC 8505C cells. PEAK1 depletion alone promotes cell cycle arrest, but not affect cell apoptosis.PEAK1 depletion sensitized 8505C cells to vemurafenib by promoting cell cycle arrest and inducing cell apoptosis. Vemurafenib could quickly inhibit ERK phosphorylation (pERK1/2), but quickly reactivate pERK1/2 in 8505C cells. Vemurafenib could only quickly activate AKT phosphorylation (pAKT) and slightly activate phosphorylation JNK1/2(pJNK1/2). However, vemurafenib in combination with PEAK1 deletion inhibited reactivation of pERK1/2 and pAKT activation, and promoted pJNK1/2. Vemurafenib transiently and slightly upregulated pro-apoptotic PUMA and Bim expression, which was quickly disappeared with long time vemurafenib treatment. Combined PEAK1 depletion and Vemurafenib treatment upregulated JNK1/2-dependant Bim and AKT-dependant PUMA expression. PUMA and Bim upregulation is critical for vemurafenib induced apoptosis in presence of PEAK1 deletion. Vemurafenib resistance in 8505C cells is associated with PEAK1 activation, pERK1/2 re-activation, pJNK1/2 inactivation and AKT activation, resulting in the inhibition of AKT-dependent PUMA and pERK1/2-pJNK1/2-dependent Bim expression. PEAK1 depletion could inhibited both ERK1/2 and AKT signal and released PUMA and Bim from vemurafenib-treated cells, resulting in the enhancing cell apoptosis. Therefore, targeting PEAK1 may be an effective strategy to sensitize BRAF-mutant ATC to vemurafenib.
- 30 January 2024
- Published by Wiley
Open AccessTargeting PEAK1 sensitizes anaplastic thyroid carcinoma 8505C cells to BRAFV600E inhibitor Vemurafenib in vitro
Vemurafenib, one of the selective BRAF inhibitor, is less effective in BRAF-mutant thyroid cancer, including anaplastic thyroid cancer (ATC), the mechanisms of which are still lacking. Pseudopodium-enriched atypical kinase 1 (PEAK1) has been demonstrated to be upregulated in human malignancies. Enhanced PEAK1 expression facilitates tumor cell survival and chemoresistance. Here we investigated the role and mechanisms of targeting PEAK1 in reversing vemurafenib resistance in ATC 8505C cells. PEAK1 depletion alone promotes cell cycle arrest, but not affect cell apoptosis.PEAK1 depletion sensitized 8505C cells to vemurafenib by promoting cell cycle arrest and inducing cell apoptosis. Vemurafenib could quickly inhibit ERK phosphorylation (pERK1/2), but quickly reactivate pERK1/2 in 8505C cells. Vemurafenib could only quickly activate AKT phosphorylation (pAKT) and slightly activate phosphorylation JNK1/2(pJNK1/2). However, vemurafenib in combination with PEAK1 deletion inhibited reactivation of pERK1/2 and pAKT activation, and promoted pJNK1/2. Vemurafenib transiently and slightly upregulated pro-apoptotic PUMA and Bim expression, which was quickly disappeared with long time vemurafenib treatment. Combined PEAK1 depletion and Vemurafenib treatment upregulated JNK1/2-dependant Bim and AKT-dependant PUMA expression. PUMA and Bim upregulation is critical for vemurafenib induced apoptosis in presence of PEAK1 deletion. Vemurafenib resistance in 8505C cells is associated with PEAK1 activation, pERK1/2 re-activation, pJNK1/2 inactivation and AKT activation, resulting in the inhibition of AKT-dependent PUMA and pERK1/2-pJNK1/2-dependent Bim expression. PEAK1 depletion could inhibited both ERK1/2 and AKT signal and released PUMA and Bim from vemurafenib-treated cells, resulting in the enhancing cell apoptosis. Therefore, targeting PEAK1 may be an effective strategy to sensitize BRAF-mutant ATC to vemurafenib.
- 2 May 2016
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 73 (2) , 79-83
Cervical lymph node thyroglobulin measurement in washout of fine-needle aspirates for diagnosis of papillary thyroid cancer metastases
Background: Patients with papillary thyroid cancer (PTC) and enlarged cervical lymph nodes (CLNs) are usually assessed by fine-needle aspiration biopsy cytology (FNAB-C). Thyroglobulin (Tg) is frequently detected in washout of fine-needle aspirates (FNA) of these lymph nodes. The aim of this study was to evaluate the accuracy of the measurement of FNAB-Tg in the washout of FNAB in combination with FNAB-C to detect CLN metastases in PTC. Methods: We retrospectively evaluated 163 surgically proven CLNs. Ultrasound-guided FNAB-C and FNAB-Tg measurements were performed and the ultrasound features were evaluated. Results: The sensitivity, specificity and accuracy of FNAB-C, FNAB-Tg and FNAB-C/FNAB-Tg in diagnosis of metastatic CLNs were 85.7, 87.8 and 71.6%, were 80.5, 87 and 82.8% and were 97.1, 96.3 and 95.7%, respectively. The diagnostic sensitivity, specificity and accuracy of FNAB-C/FNAB-Tg for metastatic CLNs was significantly higher than that of FNAB-C or FNAB-Tg alone (p < 0.01). Conclusion: Combined US-guided FNAB-C and FNAB-Tg can improve the accuracy for diagnosis of metastatic CLNs in patients with PTC.
- 2 May 2016
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 73 (2) , 79-83
Cervical lymph node thyroglobulin measurement in washout of fine-needle aspirates for diagnosis of papillary thyroid cancer metastases
Background: Patients with papillary thyroid cancer (PTC) and enlarged cervical lymph nodes (CLNs) are usually assessed by fine-needle aspiration biopsy cytology (FNAB-C). Thyroglobulin (Tg) is frequently detected in washout of fine-needle aspirates (FNA) of these lymph nodes. The aim of this study was to evaluate the accuracy of the measurement of FNAB-Tg in the washout of FNAB in combination with FNAB-C to detect CLN metastases in PTC. Methods: We retrospectively evaluated 163 surgically proven CLNs. Ultrasound-guided FNAB-C and FNAB-Tg measurements were performed and the ultrasound features were evaluated. Results: The sensitivity, specificity and accuracy of FNAB-C, FNAB-Tg and FNAB-C/FNAB-Tg in diagnosis of metastatic CLNs were 85.7, 87.8 and 71.6%, were 80.5, 87 and 82.8% and were 97.1, 96.3 and 95.7%, respectively. The diagnostic sensitivity, specificity and accuracy of FNAB-C/FNAB-Tg for metastatic CLNs was significantly higher than that of FNAB-C or FNAB-Tg alone (p < 0.01). Conclusion: Combined US-guided FNAB-C and FNAB-Tg can improve the accuracy for diagnosis of metastatic CLNs in patients with PTC.